We’re excited to share that our project partner Irena Trbojevic Akmacic from Genos Ltd contributed state-of-the-art glycan analysis to a study recently published in Cardiovascular Diabetology:
📄 Longitudinal study reveals plasma glycans associations with prediabetes/type 2 diabetes in KORA study
🔗 Read the full article
The study followed more than 470 participants over 7 years and found that specific plasma N-glycans are strongly associated with the progression from normoglycemia to prediabetes and type 2 diabetes.
Key highlights:
🔹 19 glycans linked to diabetes progression, 12 remained significant after adjustment
🔹 Certain glycans (A2G2S2, A3G3S3) also connected to BMI, fasting glucose, and insulin resistance
🔹 A glycan-clinical model showed high accuracy in predicting disease progression (AUC = 0.895)
🔹 Genetic evidence supports a causal role for several glycans in glycemic deterioration
👉 These results underscore the potential of glycans as early biomarkers for diabetes risk stratification – opening the door to prevention, early diagnosis, and more targeted interventions.
This aligns perfectly with our aims in GLUCOTYPES: harnessing innovative biomarkers and advanced technologies to transform prevention of type 2 diabetes.
